|Assessment Status||Rapid review complete|
|Drug||Sodium hydrogen carbonate|
|Indication||For metabolic acidosis in chronic kidney disease.|
|Rapid review commissioned||28/09/2020|
|Rapid review completed||23/11/2020|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that sodium hydrogen carbonate (Thamicarb®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.